Cellbiotech reported increases in both revenue and operating profit for the second quarter of this year, driven by the expansion of its health supplement brand DuoLac in the domestic market and growth in exports.
The company announced on August 7 that its preliminary revenue for the second quarter reached 15.8 billion won, with an operating profit of 1.6 billion won and a net profit of 3.6 billion won. Compared to the same period last year, revenue increased by 32.8%, and operating profit rose by 28%.
For the first half of the year, cumulative revenue totaled 30.4 billion won, a 31.4% increase from the previous year. Operating profit for the period was 4.8 billion won, marking an 82.6% rise. The net profit for the second quarter stood at 3.6 billion won.
Exports also continued to grow. Cellbiotech exports its probiotics products to 55 countries, including Denmark, Turkey, Russia, and Mexico. According to the company, it accounts for approximately 50% of the total cumulative exports of probiotics from South Korea, which have reached 538.5 billion won over the past 13 years, with Cellbiotech's share at 26.88 billion won.
A representative from Cellbiotech stated, "We will strengthen the brand competitiveness of DuoLac based on our dual-coating technology and expand the presence of Korean probiotics in the global market."
The company announced on August 7 that its preliminary revenue for the second quarter reached 15.8 billion won, with an operating profit of 1.6 billion won and a net profit of 3.6 billion won. Compared to the same period last year, revenue increased by 32.8%, and operating profit rose by 28%.
For the first half of the year, cumulative revenue totaled 30.4 billion won, a 31.4% increase from the previous year. Operating profit for the period was 4.8 billion won, marking an 82.6% rise. The net profit for the second quarter stood at 3.6 billion won.
Exports also continued to grow. Cellbiotech exports its probiotics products to 55 countries, including Denmark, Turkey, Russia, and Mexico. According to the company, it accounts for approximately 50% of the total cumulative exports of probiotics from South Korea, which have reached 538.5 billion won over the past 13 years, with Cellbiotech's share at 26.88 billion won.
A representative from Cellbiotech stated, "We will strengthen the brand competitiveness of DuoLac based on our dual-coating technology and expand the presence of Korean probiotics in the global market."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.